OptimizeRx Announces Proposed Public Offering of Common Stock
08 Februar 2021 - 10:17PM
OptimizeRx Corporation (Nasdaq: OPRX) (“OptimizeRx”), a leading
provider of digital health solutions for life science companies,
physicians and patients, today announced it has commenced an
underwritten public offering of shares of its common stock.
OptimizeRx is expected to grant the underwriters a 30-day option to
purchase up to an additional 15% of the shares of common stock
being offered at the public offering price, less underwriting
discounts and commissions. All of the shares will be offered by
OptimizeRx.
The net proceeds of the offering will be used for
general corporate purposes, which may include future acquisitions.
OptimizeRx does not have any immediate arrangements, commitments or
understandings regarding any future acquisitions.
William Blair & Company, L.L.C. and RBC Capital
Markets, LLC are acting as joint book-running managers for the
offering. The offering is subject to market conditions, and there
can be no assurance as to whether or when the offering will be
completed, or as to the actual size or terms of the offering.
An automatic shelf registration statement on Form
S-3 relating to the shares was filed with the Securities and
Exchange Commission (the “SEC”) on February 8, 2021 and is
effective. A preliminary prospectus supplement and accompanying
base prospectus relating to the offering and the shares of common
stock being offered will be filed with the SEC. Before you
invest, you should read the prospectus in the registration
statement, the preliminary prospectus supplement, and other
documents OptimizeRx has filed with the SEC for more
complete information about OptimizeRx and the offering. Copies of
the registration statement, the preliminary prospectus supplement
and accompanying base prospectus may be obtained, when available,
on the SEC’s website at http://www.sec.gov or from William Blair
& Company, L.L.C., Attention: Prospectus Department, 150 North
Riverside Plaza, Chicago, IL 60606; Phone: (800) 621-0687; Email:
prospectus@williamblair.com or RBC Capital Markets, LLC, Attn:
Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY
10281-8098, by telephone at (877) 822-4089 or by email at
equityprospectus@rbccm.com.
This press release shall not constitute an offer to
sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.About
OptimizeRx
OptimizeRx is a digital health company that
provides communications solutions for life science companies,
physicians and patients. Connecting over half of healthcare
providers in the U.S. and millions of patients through a
proprietary network, the OptimizeRx digital health
platform helps patients afford and stay on medications. The
platform unlocks new patient and physician touchpoints for life
science companies along the patient journey, from point-of-care, to
retail pharmacy, through mobile patient engagement.
Important Cautions Regarding
Forward-Looking Statements
Certain information contained in this press release
includes “forward-looking statements” within the meaning of The
Private Securities Litigation Reform Act of 1995, including
statements related to the proposed public offering, the filing of
the registration statement and the expected use of the net proceeds
from the offering. We may, in some cases use terms such as
“expects,” “plans,” “will” or other words that convey uncertainty
of the future events or outcomes to identify these forward-looking
statements. Our forward-looking statements are based on current
expectations that involve risks, potential changes in
circumstances, assumptions and uncertainties. Any or all of the
forward-looking statements may turn out to be wrong, or be affected
by inaccurate assumptions we might make or by known or unknown
risks and uncertainties as a result of various important factors,
including the uncertainties related to market conditions and the
completion of the public offering on the anticipated terms, or at
all. For a further description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to our
business in general, please refer to our preliminary prospectus
supplement to be filed with the Securities and Exchange Commission
(SEC) on February 8, 2021 under the heading “Risk Factors” and
those documents incorporated by reference therein, which includes
our Annual Report on Form 10-K filed with the SEC on March 26,
2020. You are cautioned not to place undue reliance on these
forward-looking statements, which are made only as of the date of
this press release. We undertake no obligation to publicly update
such forward-looking statements to reflect subsequent events or
circumstances.
OptimizeRx ContactDoug Baker,
CFOTel (248) 651-6568 x807dbaker@optimizerx.com
Media Relations Contact Maira
Alejandra, Media Relations ManagerTel (754)
245-7070 malejandra@optimizerx.com
Investor Relations ContactRon
Both, CMATel (949) 432-7557oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024